Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
RCT
ACE Report #10207
Ace Report Cover Osteoarthritis

Extended-release triamcinolone acetonide (FX006) versus placebo in knee osteoarthritis treatment


Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

Effects of a Single Intra-Articular Injection of a Microsphere Formulation of Triamcinolone Acetonide on Knee Osteoarthritis Pain: A Double-Blinded, Randomized, Placebo-Controlled, Multinational Study

J Bone Joint Surg Am. 2018 Apr 18;100(8):666-677

Contributing Authors: DJ Hunter JR Lieberman JR Johnson PG Conaghan SB Cohen VB Kraus N Bodick J Lufkin D Jevsevar F Berenbaum DG Jones AI Spitzer NP Katz DJ Burgess

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

486 patients with Kellgren-Lawrence grade II-III knee osteoarthritis were randomized to one of three groups: single intraarticular injection of 32mg extended-release triamcinolone (FX006; Flexion Therapeutics); single intraarticular injection of 40mg triamcinolone acetonide crystalline suspension (TAcs); or single intraarticular injection of placebo saline. Patients were assessed primarily with re...

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE

Please Login or Join to leave comments.